Global Plant-Based Biologics Market, By Product Type (Leaf-Based, Seeds-Based, Fruits-Based, Tubers-Based, Others), By Source Type (Carrot, Tobacco, Alfalfa, Rice, Duckweed, Moss, Others) – Competitive Landscape & Growth Potential Analysis, 2021-2031

Categories: Life Sciences

Format :

The global plant-based biologics market is expected to grow at a CAGR of 5% during the forecast period. The market is anticipated to surpass USD 31.1 million by 2031, from USD 19.1 million in 2020.

The new mammalian cell culture growth systems, which are both expensive and constrained in scalability, cannot meet the rising demand for human biologics. Recent advances in plant expression vectors, glycoengineering and downstream processing, on the other hand, have developed plants as a greater substitute to biologics output. Plants not only have the usual benefits of proper eukaryotic protein modification, but they also have the capacity to manufacture biologics at a lower cost and with greater scalability. They increase biologics development at an unparalleled rate while also assisting in the control of possible pandemics such as covid-19, Ebola, and others for improved efficacy or protection.

IMPACT OF COVID-19 ON THE GLOBAL PLANT-BASED BIOLOGICS MARKET

The global plant-based biologics industry is projected to benefit from the COVID-19 pandemic in the coming years, rendering it an attractive investment target. Plant-based medicines and vaccines are being developed by industry leaders in the fight against coronavirus. Medicago and GlaxoSmithKline, for example, have developed a plant-based vaccine called CoVLP, which is currently in clinical trials. Plant-based products' potential to target complex molecules, combined with their ease of extraction, is projected to play a major role in the manufacture of COVID-19 drugs and vaccines, driving the global plant-based biologics industry. To slow the spread of the SARS-CoV-2 virus and avoid potential outbreaks, novel diagnostics, therapeutics, and vaccines must be developed quickly. Furthermore, the development of secure and effective vaccine platforms would be crucial in developing a higher degree of preparedness for potential outbreaks. Companies such as iBio Inc. and PlantForm are using several vaccine technology systems to combat the COVID-19 pandemic.

GLOBAL PLANT-BASED BIOLOGICS MARKET INFOGRAPHICS

Source: ThinkWise Intelligence Analysis

GLOBAL PLANT-BASED BIOLOGICS MARKET DYNAMICS

MARKET DRIVER: ROBUST PIPELINE OF PLANT-BASED BIOLOGICS

Major market players have a range of biopharmaceutical products in clinical trials or pending regulatory approval. As a result, the extensive pipeline of biopharmaceutical products is expected to fuel substantial growth in the global plant-based biologics market in the near future. Protalix Biotherapeutics, a multinational plant-based biologics drug manufacturing company, for example, has one major plant-based drug candidate in their pipeline – Pegunigalsidase alfa, which is intended to be a plant cell culture-expressed and chemically modified version of the recombinant alpha-Galactosidase-A protein. In clinical trials, pegunigalsidase alfa demonstrated a favorable circulatory half-life with targeted enzyme action in Fabry disease-affected organs. The product is currently in 3 clinical trials phase. Furthermore, iBio, Inc., a plant–based biologics manufacturing company that uses FastPharming technology to produce monoclonal antibodies, antigens, bioinks, and other recombinant proteins, has three plant-based biologics in preclinical development. In terms of human disease, IBIO-100 targets fibrosis, which is a leading cause of organ failure globally.

MARKET RESTRAINT: STRINGENT REGULATORY GUIDELINES

One of the major factors expected to restrain the growth of the plant-based biologics market over the forecast period is the stringent regulatory guidelines for the development of plant-based biologics. Concerns over pollution and environmental risks are another consideration that is expected to stymie business development. Furthermore, mAbs (Monoclonal antibodies) in plants have many attractive characteristics, including a low cost and a short processing period. Furthermore, plant-derived mAbs are primarily biodefense agents that react quickly to a newly emerging/re-emerging disease or bioterror incident. However, the intense inspection of new plant varieties by public and regulatory authorities, as well as the higher costs of regulatory clearance, are likely to reduce global demand for plant-based biologics.

MARKET OPPORTUNITY: GROWING IMPLEMENTATION IN PHARMACEUTICAL SECTOR AND NOVEL TRANSIENT EXPRESSION VECTORS

Protein-based drugs currently have a stronghold on the pharmaceutical industry. These medications are created by using biotechnological methods on plants, which is known scientifically as plant-based biologics. The field of biological manufacturing is currently expanding beyond structurally complex drugs and is expected to include spheres. Protein-based biologics are currently regarded as the largest and fastest expanding fields of the pharmaceutical industry. Many existing market players are emphasizing the growing potential of plant-based biologics. Transient expression vectors, which are more advanced than conventional plant-derived biologics, have recently been developed. These biologics allow the development of cutting-edge vaccines and therapeutics to combat bioterrorism and possible pandemics. Furthermore, these plant-based biologics have advantages such as lower cost, high scalability, and eukaryotic protein modification. Furthermore, these plant-derived biologics have the potential to function as biocontrol agents for food-borne pathogens. As a result, the aforementioned factors are expected to generate profitable prospects for the growth of plant-based biologics.

MARKET THREAT: MAMMALIAN CULTURES

Biologics in the World Due to the scarcity of alternatives such as mammalian cultures, manufacturers are turning their attention to plant biologics. They not only have subject matter skills, but also key competencies. Furthermore, as the prevalence of chronic diseases rises, so will the market for these products, and to satisfy this unmet need, plant-based biologics provide an excellent alternative. In the United States, six out of every ten individuals have a chronic illness, and four out of every ten have at least two.

KEY TRENDS IN THE GLOBAL PLANT-BASED BIOLOGICS MARKET

GLOBAL PLANT-BASED BIOLOGICS MARKET TRENDS, BY PRODUCT TYPE

"During the forecast period, the Plant-Based Biologics market for Leaf-based biologics is expected to dominate the global market."

Of all components, leaf-based biologics are projected to have the largest market share during the forecast period. Leaf-based biologics are ideal for producing a wide range of recombinant proteins and antibodies. Leaf-based biologics have a wide range of therapeutic properties in addition to being a rich source of phenolic compounds. Furthermore, studies show that vine leaf extract has a significant impact on cardiovascular diseases. These factors are expected to drive the global market growth of the leaf-based segment. Furthermore, leaves have enormous potential as photosynthetic factories for the low-cost development of commercially useful bio medicines and critical industrial proteins. It has recently been demonstrated that vine leaves have many health benefits, including ten times the antioxidant activity of pulp or grape juice. These key elements are expected to drive the market's growth.

GLOBAL PLANT-BASED BIOLOGICS MARKET TRENDS, BY SOURCE

"During the forecast period, the Plant-Based Biologics market for duckweed biologics is expected to be the fastest-growing segment in the global market."

The global duckweed-based biologics market has a large market share and is expected to develop at the fastest CAGR during the forecast period. Duck weed is thought to be an easy and suitable host for the study of pathogenic bacterial infection. Furthermore, duckweed may be used to conduct in-depth research on virulence factors and host-pathogen interactions. Duckweed is also known as an important method for large-scale screening in the discovery of antimicrobial chemicals. Furthermore, duckweeds are small in size and have the ability to reproduce rapidly and primarily by vegetative reproduction, resulting in genetically uniform clones. Furthermore, duckweeds are widely used as model plants in genetics, plant physiology, environmental monitoring, and ecology research.

GLOBAL PLANT-BASED BIOLOGICS MARKET TRENDS, BY REGION

" Europe holds the lucrative share in the global market."

The plant-based biologics market share in Europe is expected to grow at the fastest CAGR. Rising technical advancements, heavy investments in R&D departments, and cutting-edge innovative techniques are some of the driving factors expected to fuel demand for plant-based biologics products, and it is also expected to drive the growth of the European plant-based biologics industry. Furthermore, companies are focusing more on strategic partnerships to establish manufacturing facilities and plant-based expression technology in countries such as Spain, the Czech Republic, and Germany, which is expected to help the Asian plant-based biologics market expand.

COMPETITIVE LANDSCAPE IN THE GLOBAL PLANT-BASED BIOLOGICS MARKET

The global Plant-Based Biologics market is highly diverse and competitive, with many international players and a small number of regional and local players. Genetics GmbH, Medicago, Inc., Greenovation Biotech GmbH, Mapp Biopharmaceautical - Leaf Bio., Ventria Bioscience Inc., iBio, Planform, PhycoBiologics Inc., Kentucky Bioprocessing, Inc., are just a few of the market's major players.

RECENT ADVANCES IN THE GLOBAL PLANT-BASED BIOLOGICS MARKET

In January 2021, Leaf Expression Systems (Leaf), a contract production and engineering company announced the creation of three new products to aid research into the New Coronavirus pandemic.
In August 2020, ZYUS announced constructive breakthrough in plant-based covid-19 vaccine antigen production.

CHAPTER 1. INTRODUCTION
1.1. KEY OBJECTIVES OF THE STUDY
1.2. MARKET SCOPE & DEFINITION
1.2.1. MARKET SEGMENTATION
1.3. REPORT DESCRIPTION
1.4. LIMITATIONS
1.5. STAKEHOLDERS FOR PRIMARY INTERVIEWS

CHAPTER 2. RESEARCH METHODOLOGY
2.1. DATA EXPLORATION
2.1.1. PRIMARY DATA
2.1.1.1. DATA SOURCES
2.1.1.2. KEY DATA COLLECTED
2.1.2. SECONDARY DATA
2.1.2.1. DATA SOURCES
2.1.2.2. KEY DATA COLLECTED
2.2. MARKET SIZE ESTIMATION
2.2.1. TOP-DOWN APPROACH
2.2.2. BOTTOM-UP APPROACH
2.3. DATA BREAKDOWN & TRIANGULATION
2.4. ASSUMPTIONS & FORECAST PARAMETERS

CHAPTER 3. EXECUTIVE SUMMARY

CHAPTER 4. THINKWISE INTELLIGENCE EXCLUSIVE INSIGHTS
4.1. MARKET ATTRACTIVENESS, BY PRODUCT TYPE
4.2. MARKET ATTRACTIVENESS, BY SOURCE TYPE
4.3. MARKET ATTRACTIVENESS, BY REGION

CHAPTER 5. MARKET OVERVIEW
5.1. INTRODUCTION
5.2. GROWTH IMPACT FORCES
5.2.1. DRIVERS
5.2.2. RESTRAINTS
5.2.3. OPPORTUNITIES
5.2.4. THREATS
5.3. MARKET ECOSYSTEM & VALUE CHAIN
5.3.1. ECOSYSTEM ANALYSIS
5.3.1.1. IMPACT OF COVID-19 ON THE MARKET ECOSYSTEM
5.3.2. VALUE CHAIN ANALYSIS
5.3.2.1. IMPACT OF COVID-19 ON THE MARKET VALUE CHAIN
5.4. INNOVATION & SUSTAINABILITY MATRICES
5.4.1. PATENT MATRIX
5.4.2. REGULATORY MATRIX
5.5. PRICE MATRIX
5.5.1. IMPACT OF COVID-19 ON PRICING
5.5.2. PRICING ANALYSIS
5.5.2.1. BY PRODUCT TYPE
5.5.2.2. BY SOURCE TYPE
5.5.2.3. BY REGION
5.6. PORTER’S FIVE FORCES ANALYSIS
5.6.1. BARGAINING POWER OF SUPPLIERS
5.6.2. BARGAINING POWER OF CONSUMERS
5.6.3. THREAT OF SUBSTITUTES
5.6.4. THREAT OF NEW-ENTRANTS
5.6.5. COMPETITIVE RIVALRY INTENSITY
5.7. PESTLE ANALYSIS
5.7.1. POLITICAL
5.7.2. ECONOMICAL
5.7.3. SOCIAL
5.7.4. TECHNOLOGICAL
5.7.5. ENVIRONMENTAL
5.8. IMPACT OF COVID-19 ON GLOBAL PLANT-BASED BIOLOGICS MARKET
5.8.1. PRE-COVID MARKET SCENARIO
5.8.2. POST-COVID MARKET SCENARIO

CHAPTER 6. GLOBAL PLANT-BASED BIOLOGICS MARKET ANALYSIS, BY PRODUCT TYPE
6.1. INTRODUCTION
6.1.1. LEAF-BASED
6.1.2. SEEDS-BASED
6.1.3. FRUITS-BASED
6.1.4. TUBERS-BASED
6.1.5. OTHERS

CHAPTER 7. GLOBAL PLANT-BASED BIOLOGICS MARKET ANALYSIS, BY SOURCE TYPE
7.1. INTRODUCTION
7.1.1. CARROT
7.1.2. TOBACCO
7.1.3. ALFALFA
7.1.4. RICE
7.1.5. DUCKWEED
7.1.6. MOSS
7.1.7. OTHERS

CHAPTER 8. GLOBAL PLANT-BASED BIOLOGICS MARKET ANALYSIS, BY REGION
8.1. INTRODUCTION
8.1.1. NORTH AMERICA
8.1.1.1. UNITED STATES (U.S.)
8.1.1.2. CANADA
8.1.1.3. MEXICO
8.1.2. SOUTH AMERICA
8.1.2.1. ARGENTINA
8.1.2.2. BRAZIL
8.1.2.3. COLOMBIA
8.1.2.4. REST OF SOUTH AMERICA
8.1.3. EUROPE
8.1.3.1. GERMANY
8.1.3.2. FRANCE
8.1.3.3. UNITED KINGDOM (UK)
8.1.3.4. RUSSIA
8.1.3.5. SPAIN
8.1.3.6. ITALY
8.1.3.7. SWITZERLAND
8.1.3.8. REST OF EUROPE
8.1.4. ASIA-PACIFIC
8.1.4.1. CHINA
8.1.4.2. JAPAN
8.1.4.3. INDIA
8.1.4.4. SOUTH KOREA
8.1.4.5. AUSTRALIA
8.1.4.6. INDONESIA
8.1.4.7. SINGAPORE
8.1.4.8. MALAYSIA
8.1.4.9. REST OF ASIA-PACIFIC
8.1.5. MIDDLE EAST
8.1.5.1. EGYPT
8.1.5.2. KUWAIT
8.1.5.3. SAUDI ARABIA
8.1.5.4. UNITED ARAB EMIRATES (UAE)
8.1.5.5. REST OF MIDDLE EAST
8.1.6. AFRICA
8.1.6.1. EGYPT
8.1.6.2. NIGERIA
8.1.6.3. SOUTH AFRICA
8.1.6.4. REST OF AFRICA

CHAPTER 9. COMPETITIVE LANDSCAPE
9.1. TOP WINNING STRATEGIES
9.1.1. BY STRATEGY
9.1.2. BY REGION
9.1.3. BY YEAR
9.2. COMPETITIVE HEATMAP
9.3. PRODUCT BENCHMARKING
9.4. STRATEGIC BENCHMARKING
9.4.1. MERGERS & ACQUISITIONS
9.4.2. STRATEGIC PARTNERSHIPS & COLLABORATIONS

CHAPTER 10. PLAYER BENCHMARKING
10.1. FRAUNHOFER IME
10.1.1. BUSINESS OVERVIEW
10.1.2. PRODUCT OFFERINGS
10.1.3. FINANCIAL OVERVIEW
10.1.4. STRATEGIC BENCHMARKING
10.1.5. SWOT ANALYSIS
10.2. ELEVA GMBH
10.2.1. BUSINESS OVERVIEW
10.2.2. PRODUCT OFFERINGS
10.2.3. FINANCIAL OVERVIEW
10.2.4. STRATEGIC BENCHMARKING
10.2.5. SWOT ANALYSIS
10.3. IBIO
10.3.1. BUSINESS OVERVIEW
10.3.2. PRODUCT OFFERINGS
10.3.3. FINANCIAL OVERVIEW
10.3.4. STRATEGIC BENCHMARKING
10.3.5. SWOT ANALYSIS
10.4. ICON GENETICS GMBH
10.4.1. BUSINESS OVERVIEW
10.4.2. PRODUCT OFFERINGS
10.4.3. FINANCIAL OVERVIEW
10.4.4. STRATEGIC BENCHMARKING
10.4.5. SWOT ANALYSIS
10.5. KENTUCKY BIOPROCESSING, INC.
10.5.1. BUSINESS OVERVIEW
10.5.2. PRODUCT OFFERINGS
10.5.3. FINANCIAL OVERVIEW
10.5.4. STRATEGIC BENCHMARKING
10.5.5. SWOT ANALYSIS
10.6. MAPPBIOPHARMACEAUTICAL - LEAF BIO.
10.6.1. BUSINESS OVERVIEW
10.6.2. PRODUCT OFFERINGS
10.6.3. FINANCIAL OVERVIEW
10.6.4. STRATEGIC BENCHMARKING
10.6.5. SWOT ANALYSIS
10.7. MEDICAGO, INC.
10.7.1. BUSINESS OVERVIEW
10.7.2. PRODUCT OFFERINGS
10.7.3. FINANCIAL OVERVIEW
10.7.4. STRATEGIC BENCHMARKING
10.7.5. SWOT ANALYSIS
10.8. PHYCOBIOLOGICS INC.
10.8.1. BUSINESS OVERVIEW
10.8.2. PRODUCT OFFERINGS
10.8.3. FINANCIAL OVERVIEW
10.8.4. STRATEGIC BENCHMARKING
10.8.5. SWOT ANALYSIS
10.9. PLANTFORM
10.9.1. BUSINESS OVERVIEW
10.9.2. PRODUCT OFFERINGS
10.9.3. FINANCIAL OVERVIEW
10.9.4. STRATEGIC BENCHMARKING
10.9.5. SWOT ANALYSIS
10.10. VENTRIA BIOSCIENCE INC.
10.10.1. BUSINESS OVERVIEW
10.10.2. PRODUCT OFFERINGS
10.10.3. FINANCIAL OVERVIEW
10.10.4. STRATEGIC BENCHMARKING
10.10.5. SWOT ANALYSIS